Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche experiences second failure in Alzheimer's disease

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 15, 2022 5:53pm

135 Views

Post# 35101481

RE:RE:RE:RE:Roche experiences second failure in Alzheimer's disease

And on the heels of the New York Times article in April 2022, Cassava Sciences stock price appreciated from approximately $19.00 in April 2022 to $51.00 in September 2022. A good example of Hcallahan44's "pump" on negative news at work again ! These bad actors have NO credibility and needed to be exposed.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario